Salix Pharmaceuticals received an FDA approval for Metozolv (metoclopramide), a treatment for diabetic gastroparesis and gastroesophageal reflux disease (GERD). The drug was approved for short-term use, from four to 12 weeks.
The regimen's anticipated average price of $80,000 is expected to determine how competitors stay competitive.
Haymarket Media Group launched an American version of the publisher's Campaign UK media brand this week.
Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.